Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: End Stage Renal Disease, Chronic Kidney Disease
Interventions: TRF (Tocotrienol-rich-fraction), Placebo; Dietary Supplement
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Female Sexual Arousal Disorder
Interventions: Caffeine, Placebo; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Libido, Intimacy, Gastrointestinal Issues
Interventions: Reset, Stay Ready Fiber, Libido, Testosterone supplement; Dietary Supplement
Lead sponsor: 906 CMVI Holdings; Industry
Eligibility: 18 Years to 44 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Hot Flushes
Interventions: vilazodone, placebo capsules; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vasomotor Symptoms, Postmenopausal Disorders
Interventions: JDS-HF 3.0, Placebo; Dietary Supplement
Lead sponsor: Bonafide Health; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Birmingham, Alabama • Lake Worth, Florida • Idaho Falls, Idaho

Conditions: Neoplasms
Interventions: GSK3326595, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • New York, New York + 3 more

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, Favezelimab, Lenvatinib, Quavonlimab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 19
States / cities: Tempe, Arizona • Sacramento, California • San Francisco, California + 15 more

Conditions: Pharmacokinetic Assessments in Healthy Volunteers
Interventions: PPI-668 tablet, PPI-668 capsule; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Insomnia Disorder
Interventions: ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg, Zolpidem, Placebo 1, Placebo 2; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Santa Monica, California • Upland, California • Brandon, Florida + 12 more

Conditions: Traumatic Brain Injury, Mild Traumatic Brain Injury, Post-Concussion Syndrome
Interventions: Sildenafil Citrate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension (HTN), Hypertension
Interventions: Arugula Extract, Psyllium Husk; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Major Depressive Disorder
Interventions: TC-5214, Duloxetine, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Beverly Hills, California • Chino, California • Garden Grove, California + 22 more

Conditions: Overweight, Metabolic Syndrome X
Interventions: Placebo, Cr-400, Cr-800, PE-500, PE-1000; Dietary Supplement
Lead sponsor: Kerry Group P.L.C; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Schizophrenia
Interventions: PF-04958242, Ketamine, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
Interventions: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more

Conditions: Malignant Melanoma, Colorectal Carcinoma
Interventions: PLX4032; Drug
Lead sponsor: Plexxikon; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 2 more

Conditions: Sickle Cell Disease
Interventions: VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID; Drug
Lead sponsor: Vifor (International) Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions: Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Vomiting of Pregnancy
Interventions: Ondansetron; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hot Flashes, Menopause
Interventions: Omega 3 fatty acid vitamins, Placebo capsules; Dietary Supplement
Lead sponsor: Christiana Care Health Services; Other
Eligibility: Up to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Systemic Lupus Erythematosus
Interventions: Hydroxychloroquine, Placebo Oral Capsule; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 15 Years to 49 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Great Neck, New York + 4 more

Conditions: Chronic Pancreatitis
Interventions: Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Conditions: Diabetes
Interventions: Gut motility quantification using a capsule after initiating GLP-1RA therapy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ulcerative Colitis
Interventions: AVX 470, Placebo; Drug
Lead sponsor: Avaxia Biologics, Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more

Search by objective public record fields.

Palm Tocotrienols in Chronic Hemodialysis (USA)

Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women

A Clinical Study to Evaluate the Efficacy of Four Supplements on Improving Readiness for Intimacy

Vilazodone for Menopausal Hot Flashes

Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Cerebrovascular Reactivity in American Football Players

Under Pressure: Arugula Extract's Effect on Blood Pressure in Hypertensive Individuals

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Safety Study of PLX4032 in Patients With Solid Tumors

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

CiPA Phase 1 ECG Biomarker Validation Study

Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.

Study of Anti-Malarials in Incomplete Lupus Erythematosus

Trial of Indomethacin in Chronic Pancreatitis

Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis